Dabigatran dans la fibrillation auriculaire: Études cliniques, intérêts et limites

Translated title of the contribution: Clinical studies, the interests and limits of using dabigatran in atrial fibrillation

A. Sternotte, J. Douxfils, F. Mullier, J.-M. Dogné, B. Chatelain, Christian Chatelain, A. Spinewine

Research output: Contribution to journalReview articlepeer-review

98 Downloads (Pure)


Atrial fibrillation (AF) is the most frequent cardiac arrhythmia, especially in older people. This condition is associated with an increased risk of stroke, and long-term anticoagulation treatment is therefore needed. Vitamin K antagonists are effective in reducing the risk of stroke but optimal use of these drugs remains difficult. The development of new oral anticoagulant drugs is therefore highly relevant. Dabigatran is an oral direct thrombin inhibitor. Its prodrug, dabigatran etexilate, is marketed under the name of Pradaxa and was initially approved for the prevention of thromboembolic events in major orthopedic surgery. It has been recently approved for stroke prevention in patients with AF. The purpose of this paper is to review--in light of current knowledge--the interests and limits of using dabigatran etexilate in AF. Briefly, dabigatran etexilate is not inferior to warfarin in AF. However many questions remain unanswered, including questions related to the concomitant use of dabigatran etexilate and acetylsalicylic acid, the possible increased risk of myocardial infarction and the need for drug monitoring.
Translated title of the contributionClinical studies, the interests and limits of using dabigatran in atrial fibrillation
Original languageFrench
Pages (from-to)8-17
Number of pages10
JournalJournal de Pharmacie de Belgique
Issue number1
Publication statusPublished - Mar 2012


  • Aged
  • Anti-Arrhythmia Agents
  • Anticoagulants
  • Antidotes
  • Atrial Fibrillation
  • Benzimidazoles
  • Clinical Trials as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Female
  • Humans
  • Male
  • Monitoring, Physiologic
  • Platelet Aggregation
  • Stroke
  • Thromboembolism
  • Warfarin
  • beta-Alanine


Dive into the research topics of 'Clinical studies, the interests and limits of using dabigatran in atrial fibrillation'. Together they form a unique fingerprint.

Cite this